Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Non-invasive Induction of Metaplasticity for Amblyopia

NCT: NCT07846397 · NOT_YET_RECRUITING

NCT IDNCT07846397
StatusNOT_YET_RECRUITING
Start Date2026-11
Completion2027-03
SponsorBoston Children's Hospital (OTHER)
First posted
Last updated

Brief Summary

The goal of this clinical trial is to determine the efficacy of flicker therapy as an adjunct therapy to treat amblyopia beyond the critical period in adolescents and adults aged 14-40 years who have amblyopia of ≥3 lines of interocular best-corrected (with glasses) visual acuity difference. The main questions it aims to answer are: * Does flicker therapy enable clinically meaningful and durable visual recovery from amblyopia? * Do flicker therapy-treated patients show a change in amblyopic eye visual acuity (lines)? Participants will undergo daily flicker therapy for 1 hour per day.

Frequently Asked Questions

What is Non-invasive Induction of Metaplasticity for Amblyopia?

Non-invasive Induction of Metaplasticity for Amblyopia is a clinical trial registered under NCT07846397. Current status: NOT_YET_RECRUITING.

What is the status of NCT07846397?

The current status of NCT07846397 (Non-invasive Induction of Metaplasticity for Amblyopia) is: NOT_YET_RECRUITING.

When did Non-invasive Induction of Metaplasticity for Amblyopia start?

Non-invasive Induction of Metaplasticity for Amblyopia started on 2026-11.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑